ライフサイエンスコーパス: sideroblast

1 d dysplasia and 15% or more bone marrow ring sideroblasts.

2 ts with myeloid neoplasm and 1% or more ring sideroblasts.

3 lated with unilineage dysplasia without ring sideroblasts.

4 r a diagnosis of refractory anemia with ring sideroblasts.

5 scovered in a distinct form of MDS with ring sideroblasts.

6 f myelodysplastic syndrome (MDS) with ringed sideroblasts.

7 O) therapy for refractory anemia with ringed sideroblasts.

8 n, and bone marrow and the formation of ring sideroblasts.

9 it from myelodysplastic syndromes with ring sideroblasts.

10 ry anemia (7), refractory anemia with ringed sideroblasts (5), refractory anemia with excess blasts (

11 s blasts (35), refractory anemia with ringed sideroblasts (9), and refractory anemia with excess blas

12 d leukemia (aCML; n = 71), MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T; n = 71),

13 S/MPD-U entity refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T).

14 refractory anemia (RA); 5 had RA with ringed sideroblasts; and 2 had RA with excess blasts.

15 and >500 IU/L); presence of 15% or more ring sideroblasts; and presence of SF3B1 mutations.

16 Ring sideroblasts are found also in other MDS subtypes, such

17 eloid leukemia, MDS/MPN-Unclassifiable, ring sideroblasts associated with marked thrombocytosis, and

18 n(s) in our cohort of MDS patients with ring sideroblasts can arise from CD34(+)CD38(-)CD45RA(-)CD90(

19 e of RARS/RARS-T is the presence of abnormal sideroblasts characterized by iron overload in the mitoc

20 risk (refractory anemia [RA]/RA with ringed sideroblasts/chronic myelomonocytic leukemia with < 5% b

21 define a subgroup of patients with the ring sideroblast form of MDS and a favorable prognosis.

22 eloid precursors, excess iron stores, ringed sideroblasts, iron incorporation in plasma cells, and va

23 Ring sideroblast isolation combined with state-of-the-art mul

24 Among other patients with ring sideroblasts, lower prevalence of SF3B1 mutations and hi

25 Myelodysplastic syndromes with ring sideroblasts (MDS-RS) commonly develop from hematopoieti

26 ients with myelodysplastic syndrome and ring sideroblasts (MDS-RS) present with symptomatic anemia du

27 ents with myelodysplastic syndrome with ring sideroblasts (MDS-RS).

28 quent in myelodysplastic syndromes with ring sideroblasts (MDS-RS; approximately 75% incidence) and S

29 endent anemia in patients with MDS with ring sideroblasts, most of whom carry a somatic SF3B1 mutatio

30 ndromes, including non-mutated SF3B1 or ring sideroblast-negative subgroups.

31 efractory anemia/refractory anemia with ring sideroblasts [RA/RARS]) have low levels of NF-kappaB act

32 ed in 60%-80% of refractory anemia with ring sideroblasts (RARS) and RARS associated with thrombocyto

33 cantly between refractory anemia with ringed sideroblasts (RARS) and refractory anemia with multiline

34 Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS)

35 refractory anemia (RA), 3 had RA with ringed sideroblasts (RARS), 5 had RA with excess blasts (RAEB),

36 penia with multilineage dysplasia and ringed sideroblasts (RCMD-RS) and UPD4q24, and five patients (r

37 topenia with multilineage dysplasia and ring sideroblasts (RCMD-RS).

38 nemia with multilineage dysplasia and ringed sideroblasts (RCMD/RS) with regard to therapeutic respon

39 actory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refr

40 he presence of >/= 15% bone marrow (BM) ring sideroblasts (RS) and < 5% blasts is required for a diag

41 myelodysplastic syndromes (LR-MDS) and ring sideroblasts (RS) relapsed or refractory to erythropoiet

42 s (MDSs), especially in the presence of ring sideroblasts (RSs).

43 on (<=200 U/L vs >200 to <500 U/L), and ring sideroblast status (positive vs negative).

44 serum erythropoietin concentration, and ring sideroblast status, and randomly allocated (1:1) to rece

45 atients with the refractory anemia with ring sideroblasts subtype of myelodysplastic syndrome (MDS) h

46 B1 mutation with refractory anemia with ring sideroblasts, TET2/SRSF2 comutation with chronic myelomo

47 In contrast, we found typical ring sideroblasts that accumulated iron mostly in mitochondri

48 HSCs differentiated into characteristic ring sideroblasts, the hallmark of MDS-RS.

49 role for erythroid differentiation and ring sideroblasts themselves in SF3B1-mutant myelodysplastic

50 ions are prevalent in low-risk MDS with ring sideroblasts, whereas U2AF1 and SRSF2 mutations are freq

51 uency among conditions characterized by ring sideroblasts, which is consistent with a causal relation

52 ational Prognostic Scoring System) with ring sideroblasts who had been receiving regular red-cell tra

53 wer-risk myelodysplastic syndromes with ring sideroblasts who had been receiving regular red-cell tra

54 Conversely, MDS with ring sideroblasts with nonmutated SF3B1 segregated in differe